Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-Current Deffered Revenue (2021 - 2025)

Lyra Therapeutics has reported Non-Current Deffered Revenue over the past 5 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $11.9 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (changed 0.0% YoY), and the annual figure for FY2025 was $11.9 million, changed 0.0%.
  • Non-Current Deffered Revenue for Q4 2025 was $11.9 million at Lyra Therapeutics, roughly flat from $11.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for LYRA hit a ceiling of $14.1 million in Q4 2022 and a floor of $1.9 million in Q4 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $11.9 million (2024), compared with a mean of $10.7 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 630.89% in 2022 and later decreased 13.79% in 2023.
  • Lyra Therapeutics' Non-Current Deffered Revenue stood at $1.9 million in 2021, then soared by 630.89% to $14.1 million in 2022, then fell by 13.79% to $12.1 million in 2023, then decreased by 2.26% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.